Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids
The DOI matches its Crossref record.
Abstract
To evaluate the long-term effects of treatment with RU486 and to test its efficacy in endometriosis, a 3-month trial was conducted to evaluate the effects of daily administration (100 mg/day or approximately 2 mg/kg/day) on the functional activity of the reproductive axis, as well as implants, in patients with symptomatic pelvic endometriosis. All women became amenorrhoeic and acyclic. However, ovarian suppression was incomplete. In 24 h sampling studies, mean luteinizing hormone (LH) and LH pulse amplitude were increased without a change in LH pulse frequency. Additionally, an antiglucocorticoid effect was demonstrated. Treatment resulted in improvement in pelvic pain in all subjects without significant changes in the extent of disease as evaluated by laparoscopy. We also attempted to reduce the growth of uterine fibroids by using 50 mg/day of RU486 for 3 months in 10 patients. Myoma size decreased approximately 22% at 4 weeks, 39% at 8 weeks and 49% at 12 weeks. Serum concentrations of LH, androstenedione and testosterone increased in the first 3 weeks of treatment and then returned to baseline. In conclusion, daily administration of RU486 resulted in ovarian inhibition and menstrual acyclicity and in an improvement in the pain associated with pelvic endometriosis and decreased the size of uterine fibroids. This ovarian inhibition was achieved without oestrogen deprivation and may provide a novel long-term approach to the treatment of ovarian steroid-dependent disease processes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?
Marquardt, R. M., Kim, T. H., Shin, J.-H., & Jeong, J.-W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153822 · Cited by 491
Sex steroidal regulation of uterine leiomyoma growth and apoptosis
Maruo, T. (2004) · Human Reproduction Update · doi:10.1093/humupd/dmh019 · Cited by 294
Current and emerging treatment options for endometriosis
Ferrero, S., Evangelisti, G., & Barra, F. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1494154 · Cited by 152
Medical management of endometriosis-associated pain
Mahutte, N. G., & Arici, A. (2003) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(02)00057-8 · Cited by 68
“In small, open-label, cohort studies, doses of mifepristone, 50 to 100 mg/day, have been shown to induce amenorrhea (without hypoestrogenism) and lower pain scores [76,77].”
BackgroundA comprehensive review of hormonal and biological therapies for endometriosis: latest developments
Barra, F., Grandi, G., Tantari, M., Scala, C., Facchinetti, F., & Ferrero, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1581761 · Cited by 69
Metadata
- Authors
- Kettel, L. M., Murphy, A. A., Morales, A. J., & Yen, S. S. C.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 1994-06-01
- Volume
- 9
- Issue
- suppl 1
- Pages
- 116-120
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2070526307
- Cited by
- 95
- References
- 0
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. https://app.cochat.ai/papers/10.1093/humrep/9.suppl_1.116
- The paper
- Kettel, L. M., Murphy, A. A., Morales, A. J., & Yen, S. S. C. (1994). Clinical efficacy of the antiprogesterone RU486 in the treatment of endometriosis and uterine fibroids. Human Reproduction. https://doi.org/10.1093/humrep/9.suppl_1.116
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.